Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Kraft Heinz Co (KHC) vs Eli Lilly And Co (LLY) Price & Performance

Kraft Heinz CoTrade
Eli Lilly And CoTrade

Price performance (Past 24H)

Key statistics

Kraft Heinz Co vs Eli Lilly And Co — how do they compare? Kraft Heinz Co trades at $24.68 (market cap $29.56B), while Eli Lilly And Co trades at $1,214.01 (market cap $1.10T). The key difference: Eli Lilly And Co is far larger — about 37.2× Kraft Heinz Co's market cap, and Kraft Heinz Co pays the higher dividend (6.42%). Which is the better fit depends on your goals.

KHCLLY
Market Cap
$29.56B$1.10T
Sector
Consumer StaplesHealth
52-Week High
$28.06$1.24K
52-Week Low
$21.21$639.43
Enterprise Value
$45.88B$1.14T
Dividend Yield
6.42%0.56%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Kraft Heinz Co

Kraft Heinz (KHC) trades at $25.32, up 1.44% today, with a bearish technical signal but oversold RSI. The stock shows mixed fundamentals: earnings beat estimates in recent quarters, yet 2025 net income was -$5.85B, reflecting margin pressures. Revenue declined to $24.94B in 2025, while the P/E of 13.04 and P/B of 0.83 suggest undervaluation. Recent news highlights CEO Cahillane's strategy to boost marketing spend for growth, amid institutional selling by firms like Bank of America (Defense World, 2026-08-09).

Outlook remains cautious; the 6% dividend yield attracts income investors, but sustainability is questioned amid profit declines. Risks include persistent inflation and competitive headwinds. Analysts are mostly neutral (57.14% Hold), with a $24 consensus target, implying limited upside. The stock's trajectory hinges on successful execution of turnaround efforts to stabilize earnings.

Eli Lilly And Co

Eli Lilly (LLY) trades at $1,185.71, down 0.59% on the day, with a bullish technical signal from moving averages and strong fundamental momentum. The company reported Q2 2026 revenue growth of 48% to $23 billion, beating estimates, driven by demand for Mounjaro and Zepbound. Valuation ratios like P/E of 39.8 and P/S of 13.34 reflect high growth expectations, while profitability remains robust with a net income margin of 33.53%.

Outlook is positive due to pipeline advancements like retatrutide and raised 2026 guidance, but risks include competitive pressures and regulatory scrutiny. Analysts are bullish with a consensus price target of $1,380, citing sustained double-digit growth and market leadership in weight-loss drugs as key drivers for upside.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Kraft Heinz Co

In July 2015, Kraft merged with Heinz to create the third-largest food and beverage manufacturer in North America behind PepsiCo and Nestle and the fifth-largest player in the world. Beyond its namesake brands, the combined firm's portfolio includes Oscar Mayer, Velveeta, and Philadelphia. Outside North America, the firm's global reach includes a distribution network in Europe and emerging markets that drive around one fifth of its consolidated sales base, as its products are sold in more than 190 countries and territories.

Read more on KHC

About Eli Lilly And Co

Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer

Read more on LLY